Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001104659-18-024891
Filing Date
2018-04-18
Accepted
2018-04-18 17:22:21
Documents
1
Period of Report
2018-04-18

Document Format Files

Seq Description Document Type Size
1 3 a3.html 3  
1 3 a3.xml 3 5816
  Complete submission text file 0001104659-18-024891.txt   7949
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38459 | Film No.: 18761890
SIC: 2834 Pharmaceutical Preparations

Mailing Address 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139
Business Address 250 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 (617) 871-8000
Novartis Institutes for BioMedical Research, Inc. (Reporting) CIK: 0001673852 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38459 | Film No.: 18761891

Mailing Address 50 HAMPSHIRE STREET, 8TH FLOOR CAMBRIDGE MA 02139
Business Address 50 HAMPSHIRE STREET, 8TH FLOOR CAMBRIDGE MA 02139 617-714-4096
Surface Oncology, Inc. (Issuer) CIK: 0001718108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)